Wills Hughes-Wilson
Corporate Officer/Principal at MEREO BIOPHARMA GROUP PLC
Net worth: 1 010 $ as of 2024-03-30
Profile
Wills Hughes-Wilson is currently the Chief Patient Access & Commercial Planning at Mereo BioPharma Group Plc.
Previously, she held positions as the Executive Director at European Biopharmaceutical Enterprises, Vice President-Health & Market Access Policy at Genzyme Corp., and VP-Health & Market Access Policy EMEA at Genzyme Therapeutics Ltd.
From 2016 to 2018, she served as the Chief Patient Access Officer & Senior VP at Swedish Orphan Biovitrum AB.
Ms. Hughes-Wilson graduated from the University of Durham.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2024-01-24 | 1,530 ( 0.00% ) | 1 010 $ | 2024-03-30 |
Wills Hughes-Wilson active positions
| Companies | Position | Start |
|---|---|---|
| MEREO BIOPHARMA GROUP PLC | Corporate Officer/Principal | 2018-02-28 |
Former positions of Wills Hughes-Wilson
| Companies | Position | End |
|---|---|---|
| SWEDISH ORPHAN BIOVITRUM AB | Public Communications Contact | 2017-12-31 |
Genzyme Therapeutics Ltd.
 Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Genzyme Therapeutics Ltd. develops transformative therapies for patients affected by rare and debilitating diseases. Its treatment areas include thyroid cancer, sclerosis, Fabry disease and Pompe. The company was founded on November 5, 2001 and is headquartered in Oxford, the United Kingdom. | Corporate Officer/Principal | - |
European Biopharmaceutical Enterprises
 European Biopharmaceutical Enterprises BiotechnologyHealth Technology European Biopharmaceutical Enterprises develops biological products. The private company is based in Brussels, Belgium. | Director/Board Member | - |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
Training of Wills Hughes-Wilson
| University of Durham | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| SWEDISH ORPHAN BIOVITRUM AB | Health Technology |
| MEREO BIOPHARMA GROUP PLC | Health Technology |
| Private companies | 3 |
|---|---|
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Genzyme Therapeutics Ltd.
Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Genzyme Therapeutics Ltd. develops transformative therapies for patients affected by rare and debilitating diseases. Its treatment areas include thyroid cancer, sclerosis, Fabry disease and Pompe. The company was founded on November 5, 2001 and is headquartered in Oxford, the United Kingdom. | Health Technology |
European Biopharmaceutical Enterprises
European Biopharmaceutical Enterprises BiotechnologyHealth Technology European Biopharmaceutical Enterprises develops biological products. The private company is based in Brussels, Belgium. | Health Technology |
- Stock Market
- Insiders
- Wills Hughes-Wilson
